- Trial phase
- Approved
- Time to market
- Already on the market, approved since 2008 (IR) and 2011 (ER)
- Why 4/10
- Nucynta ER is already FDA-approved and commercialized with no pending regulatory binary (PDUFA/pivotal readout) in the next 12+ months. Per the rubric, an approved, marketed drug with no imminent new regulatory decision scores 3-5. A score of 4 reflects that while Nucynta ER is part of Collegium's commercial portfolio, it is not the primary growth driver, the company's focus has shifted to its ADHD franchise (Jornay PM, AZSTARYS) and other pain products. The stock does have a near-term catalyst in Q3 earnings (Nov 5, 2026), but that is a quarterly report, not a drug-specific binary.
Nucynta ER itself is not a catalyst for COLL. The stock's next binary event is Q3 2026 earnings on November 5, 2026, where the market will focus on guidance for the integrated portfolio including the AZSTARYS acquisition. Investors should watch for Nucynta's ongoing revenue erosion from generic tapentadol, and whether Collegium's ADHD pivot can offset pain-portfolio declines to justify the analyst consensus ~$49 target.
Price Chart
Executive Summary
Nucynta ER (tapentadol hydrochloride extended-release) is a Schedule II opioid analgesic that has been FDA-approved since 2011 and is commercialized by Collegium Pharmaceutical (Nasdaq: COLL). It is a mature product in a diversified portfolio that now includes Xtampza ER, Belbuca, Jornay PM, and the recently acquired AZSTARYS (ADHD). With no upcoming regulatory binary for this specific drug, its investment impact is limited, Nucynta is a legacy revenue contributor facing generic erosion rather than a catalyst for COLL shares. The stock itself screens as attractive on valuation (analyst mean target ~$49 vs ~$23 current price, 113% implied upside) but is down ~55% from its 52-week high amid portfolio transition and high short interest (~17% of shares outstanding).
How It Works
Nucynta ER is an extended-release opioid painkiller. Its active ingredient, tapentadol, works in two ways: it activates the brain's opioid receptors (similar to morphine but weaker) and also inhibits the reuptake of norepinephrine, a chemical involved in pain signaling. This dual mechanism makes it effective for moderate to severe chronic pain. It is a Schedule II controlled substance with abuse and addiction risks, carrying an FDA boxed warning for addiction, abuse, misuse, and life-threatening respiratory depression.
Trial Status
Nucynta ER was approved by the FDA on August 25, 2011. Nucynta immediate-release was originally approved on November 20, 2008. The most recent FDA action was a supplemental labeling approval on December 22, 2025 (NDA 022304). The drug is marketed and commercialized; no further clinical trials are underway for this already-approved molecule.
The Two-Sided Case
Upcoming Catalysts
- No upcoming regulatory catalyst for Nucynta ER specifically, it is an already-approved commercial product
- COLL Q3 2026 earnings report scheduled November 5, 2026 (consensus EPS ~$1.86, revenue ~$216M)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
COLLEGIUM PHARMACEUTICAL, INC 8-K COLL ·Originating report